A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole

Publisher： Bentham Science Publishers

E-ISSN： 1875-6204|3|4|305-317

ISSN： 1570-1603

Source： Current Pharmacogenomics, Vol.3, Iss.4, 2005-12, pp. : 305-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of the Metabolic Disturbances Caused by Antipsychotic Drugs: Focus on Potential Drug Interactions

By Baptista T.   N.M.K. Ng Ying Kin   Beaulieu S.  

Clinical Pharmacokinetics, Vol. 43, Iss. 1, 2004-01 ,pp. : 1-15

Adis International

Access to resources Recommend Favorite

Aripiprazole in the treatment of Alzheimer's disease

By De Deyn Peter Paul   Drenth Annemieke FJ   Kremer Berry P   Oude Voshaar Richard C   Van Dam Debby  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 4, 2013-03 ,pp. : 459-474

Informa Healthcare

Access to resources Recommend Favorite

Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D 2 receptor following repeated treatment in the rat striatum

By Inoue A.   Miki S.   Seto M.   Kikuchi T.   Morita S.   Ueda H.   Misu Y.   Nakata Y.  

European Journal of Pharmacology, Vol. 321, Iss. 1, 1997-02 ,pp. : 105-111

Elsevier

Access to resources Recommend Favorite

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT 1A receptor

By Jordan S.   Koprivica V.   Chen R.   Tottori K.   Kikuchi T.   Altar C.A.  

European Journal of Pharmacology, Vol. 441, Iss. 3, 2002-04 ,pp. : 137-140

Elsevier

Access to resources Recommend Favorite

Aripiprazole: novel antipsychotic may lessen risk of metabolic disorders

By  

Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. : 18-20

Adis International

Access to resources Recommend Favorite